Active and chronic antibody-mediated rejection (AMR) is a common cause of graft failure. Prognostic markers of this complication are not well defined. We aimed to find out the demographic, histopathological and clinical characteristics of transplant recipients who developed AMR and to evaluate the impact of these features as well as antirejection treatment modalities on graft survival.
No takes yet. Share an insight, caveat, or question.
Ergün et al. (2021) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: